A detailed history of Vanguard Group Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,650,500 shares of CRVS stock, worth $14.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,650,500
Previous 1,493,357 10.52%
Holding current value
$14.2 Million
Previous $2.66 Million 12.98%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.36 - $2.29 $213,714 - $359,857
157,143 Added 10.52%
1,650,500 $3 Million
Q1 2024

May 10, 2024

BUY
$1.76 - $2.41 $251,194 - $343,964
142,724 Added 10.57%
1,493,357 $2.66 Million
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $3,997 - $7,105
3,701 Added 0.27%
1,350,633 $2.38 Million
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.97 $64,446 - $135,749
45,707 Added 3.51%
1,346,932 $1.97 Million
Q2 2023

Aug 14, 2023

BUY
$1.0 - $3.86 $40,659 - $156,943
40,659 Added 3.23%
1,301,225 $2.98 Million
Q4 2022

Feb 10, 2023

BUY
$0.74 - $1.04 $488 - $686
660 Added 0.05%
1,260,566 $1.07 Million
Q3 2022

Nov 14, 2022

SELL
$0.71 - $1.17 $5,570 - $9,179
-7,846 Reduced 0.62%
1,259,906 $1.03 Million
Q1 2022

May 13, 2022

BUY
$1.46 - $2.48 $52,562 - $89,284
36,002 Added 2.92%
1,267,752 $2.08 Million
Q4 2021

Feb 14, 2022

BUY
$2.34 - $5.31 $66,425 - $150,734
28,387 Added 2.36%
1,231,750 $2.97 Million
Q3 2021

Nov 12, 2021

BUY
$1.89 - $8.53 $177,934 - $803,056
94,145 Added 8.49%
1,203,363 $5.82 Million
Q2 2021

Aug 13, 2021

BUY
$2.46 - $3.14 $2.73 Million - $3.48 Million
1,109,218 New
1,109,218 $2.96 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.